Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chrysant, S.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chrysant, S.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2003; 96: 771-773
© 2003 Association of Physicians

Commentary

The ALLHAT study: results and clinical implications

S.G. Chrysant

From the Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma, Oklahoma City, USA

The first 10% of the full text of this article appears below.


   Introduction
 
The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) just published,1 is the largest clinical trial so far conducted. Under the auspices of the National Heart Lung and Blood Institute (NHLBI), it included over 40 000 high-risk hypertensive patients (aged 55 years or older) who were followed over 5 years (with the exception of the doxazosin treatment arm, which was discontinued prematurely due to a higher incidence of heart failure).2 It included 33 357 patients who were randomized to treatments, including chlorthalidone 12.5–25.0 mg/day (n = 15 255), amlodipine 2.5–10 mg/day (n = 9048) and lisinopril 10–40 mg/day (n = 9054). The doses of these drugs were increased until a blood pressure goal of < 140/90 mmHg was achieved. In addition, other drugs could . . . [Full Text of this Article]


   The results
 

   Implications for the practicing physician
 

Address correspondence to Professor S.G. Chrysant, Clinical Professor of Medicine, University of Oklahoma, 5850 W. Wilshire Blvd, Oklahoma City, OK 73132, USA. e-mail: schrysant@yahoo.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?